Alzheimer's, on the other hand, directly affects brain cells, and if there is uncertainty, patients and their families should certainly ask for a second opinion.
The population most likely to suffer from the disease is the elderly, but this is not always the case. Researchers note, "Alzheimer's disease is not part of the normal aging process, although it affects predominantly elderly people. Whereas only 10% of those 65 years of age and older are affected by this disease, the percentage may be as high as 48% in those 85 years of age and older" (Handy, Turnbull, Edwards, & Lancaster, 1998, p. 1-2). In addition, there are more rare forms that strike patients in middle age. These researchers write about, "a rare form of Alzheimer's that strikes in middle age and is passed down to 50%, on average, of offspring" (Tanzi & Parson, 2000, p. xiii). This form of the disease can spread among siblings, often attacking an entire family of brothers and sisters.
Currently, there is little in the way of prevention of this disease. Because a distinct cause is still unknown, an effective and lasting cure cannot be developed. Scientists understand that risk factors include advancing age, and a family history of the disease. Treatment is difficult, because there are so many differing forms of the disease, and scientists still do not know what causes it, or how it specifically affects the central nervous system. Some treatments include several different drug treatments with differing rates of success. Some of these drugs include: Hydergine, Tacrine, Donepezil, and many other drugs that affect specific portions of the brain. a-beta inhibitors have also been developed to deal with the disease, because of extensive research in this area. These researchers note, "As suddenly realized, the a-beta peptide wasn't just an abnormal brain byproduct derived from a cellular goof, but a molecule normally churned out by cells throughout the body. Only when it accumulated in the brain could it be considered a menace" (Tanzi & Parson, 2000, p. 212). All the major drug companies are working on different medications meant to treat Alzheimer's, because it is such a prevalent and devastating disease, and the elderly population is continually growing....
In light of the knowledge provided by these case studies, it is important to note certain flaws in the methodology of each cases study. The study in the case of midlife neuroticism, the researchers do not take into account pre- existing conditions such the brain structure and function associated with greater neuroticism. Failure to proper diagnosis might lead to early presentation of Alzheimer's disease in response to pathology. As for
2013: 1483). It notes that although genetic markers "are known for individuals of European ancestry, but whether the same or different variants account for the genetic risk of Alzheimer disease in African-American individuals" was unknown before the study (Reitz et al. 2013: 1483). In contrast, the Kolata piece seemed to suggest that the association was very much a 'known' quantity, even though it had not yet been directly proven.
Alzheimer's disease (AD) is one of the most researched ailments in the world of medicine. This discussion will explore the working hypothesis that caloric restriction may prevent Alzheimer's disease. In addition, the paper will explore the idea that individuals with the ApoE genotype and a higher intake of calories have a higher risk of AD than those who do not carry the apoE4 allele (diet-gene interaction). Let's begin the discussion
) Researcher believe that when Alzheimer's begins to attack, it hits the "factory" of cell groups that otherwise are functioning perfectly. There are breakdowns in the communications that the cell groups hitherto provided, and although scientists don't know precisely where the attack is first launched by Alzheimer's, but they do understand that "as the damage spreads, cells lose their ability to do their jobs and, eventually die, causing irreversible changes
After 13 months, the rats begin to show signs of dementia including reduced cognitive ability and memory impairment (McGill University, 2010). Amyloid B. immunotherapy Past research Past research on the effects of active or passive a? immunization on a? buildup and AD progression provided evidence that such immunization "protects against the progressive loss of synaptophysin in the hippocampal molecular layer and frontal neocortex of a transgenic mouse model of AD" (Buttini &
Alzheimer's Disease currently affects more than four million Americans. Alzheimer's is a disease characterized by the progressive degeneration of areas within the brain, resulting in cognitive and physical decline that will eventually lead to death. It is important to emphasize that Alzheimer's disease (AD) is not a normal part of aging. Although AD typically appears in those over sixty-five, it is a neurodegenerative disease, quite distinct from any aging-related cognitive
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now